Pregnant women with eczema needed for safety study on common cream

NCT ID NCT06259669

Recruiting now Knowledge-focused Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows about 958 pregnant women with mild to moderate eczema (atopic dermatitis) who use ruxolitinib cream (Opzelura) and compares them to similar women who do not use the cream. Researchers track birth defects and other pregnancy outcomes to see if the cream is linked to any problems. The goal is to gather real-world safety data, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ruxolitinib cream (Opzelura)
What this could lead to: If this study shows no increased risk of birth defects, it could provide reassurance about using ruxolitinib cream during pregnancy.
What could go wrong: This is an observational registry, not a controlled trial, so it cannot prove safety. Results may be influenced by other factors, and the study is still recruiting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema pregnancy disorder Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS PREGNANCY RELATED

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Syneos Health (remote site)
RECRUITING

Morrisville, North Carolina, 27560, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.